**Chapter 5**

*Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications*

[35] Southall NT, Natarajan M, Lau LP, Jonker AH, Deprez B, Guilliams T, et al. The use or generation of biomedical data and existing medicines to

discover and establish new treatments

recommendations of the IRDiRC Data Mining and Repurposing Task Force. Orphanet Journal of Rare Diseases.

[36] Fda.https://wwwaccessdatafdagov/ scripts/opdlisting/oopd/detailedIndexcf m?cfgridkey=632218 [Online]. Available from: https://www.accessdata.fda.gov/ scripts/opdlisting/oopd/detailedIndex. cfm?cfgridkey=632218 [Accessed:

for patients with rare diseases–

2019;**14**(1):1-8

28 February 2020]

[37] Yella JK, Yaddanapudi S, Wang Y, Jegga AG. Changing trends in computational drug repositioning. Pharmaceuticals. 2018;**11**(2):57

**78**
